12:00 AM
 | 
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Soliris eculizumab regulatory update

Alexion said the U.K. Ministers of Health deferred a decision to cover Soliris eculizumab on the NHS for atypical hemolytic uremic syndrome (aHUS). According to the company, the ministers overruled a positive recommendation to cover the drug from the Advisory Group for National...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >